Optegra continues expansion

Article

Optegra has acquired Memira's eye clinics in Munich and Stuttgart, Germany.

Optegra has acquired Memira's eye clinics in Munich and Stuttgart, Germany.

The move follows the firm's takeover of 23 of Lexum's European hospitals in the UK, Czech Republic, Germany and Poland. Optegra will continue to offer services in cataract, retinal, corneal, glaucoma and orbito-facial. Memira is a Scandinavian provider of refractive and intraocular eye surgery and will continue to expand in the Nordics.

Matthias Pertzsch, Optegra Germany Managing Director, noted, "This is an important step in our German expansion and we hope to continue to expand our national distribution further in 2013. We are actively looking for opportunities for partnership and acquisition of well-established, high-end existing ophthalmology practices."

"Combining the strength of professional medical competence with the structure, management expertise and marketing investment of Optegra will lead to lasting models of partnership between physicians and Optegra which ultimately benefit German patients."

For further details on Optegra clinics please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.